FORMULATION ARTICLES
-
Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking
RNAi therapeutics may help oncology move beyond single-target drugs by disrupting adaptive tumor survival networks driving resistance in solid tumors.
-
What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing
RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.
-
Beyond Hairpins: A New Translational Repression Assay Expands RNA-Binding Protein Research
Researchers expanded translational repression assays beyond RNA hairpins, enabling scalable study of linear RNA-protein interactions in living cells.
-
Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing Efficiency
New research shows RNA payload distribution inside LNPs — not just encapsulation efficiency — may be key to unlocking stronger in vivo gene editing performance.
-
Beyond Guanidine: Scientists Discover A Mysterious Riboswitch Variant With A Different Biological Target
Scientists identified a mysterious riboswitch variant that resembles guanidine sensors but likely evolved to detect an entirely different metabolite.
-
RNA Modification-Mediated Translational Control In Immune Cells
Exploring how m6A RNA modifications control immune cell translation, influencing inflammation, tumor immunity, T cell activation, and future immunotherapies.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Explore how lipid nanoparticles are revolutionizing cell therapy workflows to enable the precise delivery of mRNA and gene editing tools for next-generation treatments like CAR T and HSC therapies.
-
Explore the necessary components of a smooth tech transfer for LNP-based drugs, including the variables that impact LNP formulation and the outsourcing strategies needed to avoid common pitfalls.
-
The shift from "scale-up" to "scale-out" in genetic medicine enhances production speed, revolutionizing pharmaceutical manufacturing and accelerating life-saving therapies for global patient populations.
-
In this paper, we present the foundation of an mRNA-LNP platform for encoding and expressing therapeutic antibodies in vivo, eliminating the need for costly and time-consuming manufacturing.
-
Microfluidic mixing is one of the most effective means to formulate LNPs for its scalability and reproducibility. Explore LNP formulation, polishing, sterile filtration of mRNA-LNPs, and more.
-
As pharma companies aim to overcome development obstacles, it is important to incorporate GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms.
-
Learn how turbulent jet mixing enables linear scalability, guaranteeing consistent nanoparticle quality from research to commercial production and accelerating product timelines.